Organogenesis Holdings (ORGO) Receives a Buy from Oppenheimer

In a March 10 report, Steven Lichtman from Oppenheimer maintained a Buy rating on Organogenesis Holdings (ORGO), with a price target of $9.00. The company’s shares closed last Monday at $3.09, close to its 52-week low of $3.00.
In a report issued on March 6, Credit Suisse also reiterated a Buy rating on the stock with a $8.00 price target.
The company has a one-year high of $14.30 and a one-year low of $3.00. Currently, Organogenesis Holdings has an average volume of 74.83K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. Over the past quarter there has been an increase of insiders buying their shares of ORGO in relation to earlier this year.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis Holdings (ORGO) Receives a Buy from Oppenheimer